Adaptive Biotechnologies Business Separation May Unlock Greater Value

Adaptive Biotechnologies announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. William Blair analyst Andrew Brackmann believes the separation could simplify the investment story and create strategic flexibility for the MRD franchise. The Immune Medicine segment is expected to contribute little to valuation and carries $15-20 million in annual cash burn. The company also priced a $300 million convertible senior notes offering to repay debt and fund MRD initiatives.